Maina Bhaman: Ledger

Stories naming Maina Bhaman. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Role	Organisation	Sources
Partner	Sofinnova Partners	Brandon BioCatalyst portfolio (Tue 17 Nov 2020), Brandon Capital portfolio (Tue 17 Nov 2020), Brandon Capital portfolio (Mon 16 Nov 2020), Brandon BioCatalyst portfolio (Mon 16 Nov 2020)

Seed $8.2m

Myricx Pharma Launches with £4.5M (AU$8.2M) Financing to Progress its Novel NMT inhibitors in Cancer

UK biotech Myricx Pharma launched with a £4.5 million seed round from Sofinnova Partners and Brandon Capital to advance its NMT-inhibitor cancer drug discovery work.

Brandon BioCatalyst portfolio Mon 16 Nov 2020 Myricx Pharma Charles Consultants GSK Heptares Medical Research Commercialisation Fund (MRCF)Pfizer Brandon Capital Partners Sofinnova Partners Dr Andrew Bell Prof Ed Tate Maina Bhaman Dr Roberto Solari Dr Robin Carr Dr Stephen Thompson Sue Charles

Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio

Maina Bhaman

Roles

Coverage

Myricx Pharma Launches with £4.5M (AU$8.2M) Financing to Progress its Novel NMT inhibitors in Cancer